- Home
- VYGR vs TTRX Comparison
VYGR vs TTRX Comparison
Compare VYGR & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- TTRX
- Stock Information
- Founded
- VYGR 2013
- TTRX 2015
- Country
- VYGR United States
- TTRX United States
- Employees
- VYGR N/A
- TTRX N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- TTRX Biotechnology: Pharmaceutical Preparations
- Sector
- VYGR Health Care
- TTRX Health Care
- Exchange
- VYGR Nasdaq
- TTRX Nasdaq
- Market Cap
- VYGR 232.4M
- TTRX 257.8M
- IPO Year
- VYGR 2015
- TTRX N/A
- Fundamental
- Price
- VYGR $3.99
- TTRX $3.43
- Analyst Decision
- VYGR Strong Buy
- TTRX
- Analyst Count
- VYGR 7
- TTRX 0
- Target Price
- VYGR $16.17
- TTRX N/A
- AVG Volume (30 Days)
- VYGR 468.8K
- TTRX 105.2K
- Earning Date
- VYGR 11-10-2025
- TTRX 01-01-0001
- Dividend Yield
- VYGR N/A
- TTRX N/A
- EPS Growth
- VYGR N/A
- TTRX N/A
- EPS
- VYGR N/A
- TTRX N/A
- Revenue
- VYGR $31,316,000.00
- TTRX N/A
- Revenue This Year
- VYGR N/A
- TTRX N/A
- Revenue Next Year
- VYGR $107.10
- TTRX N/A
- P/E Ratio
- VYGR N/A
- TTRX N/A
- Revenue Growth
- VYGR N/A
- TTRX N/A
- 52 Week Low
- VYGR $2.65
- TTRX $2.57
- 52 Week High
- VYGR $7.44
- TTRX $26.50
- Technical
- Relative Strength Index (RSI)
- VYGR 41.99
- TTRX N/A
- Support Level
- VYGR $3.81
- TTRX N/A
- Resistance Level
- VYGR $4.30
- TTRX N/A
- Average True Range (ATR)
- VYGR 0.26
- TTRX 0.00
- MACD
- VYGR -0.01
- TTRX 0.00
- Stochastic Oscillator
- VYGR 38.14
- TTRX 0.00
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.